Search results for "phospholipid"

showing 10 items of 422 documents

Domain formation in monolayers

1995

For phospholipids at the air/water interface we demonstrate that molecular chirality in some, but not in all, cases influences the domain shapes. In other cases chirality in the head group region can cause a chiral structure considering the tail arrangement. This indicates head group ordering. Minute changes of the molecular structure may change domain morphology from circular to dendritic. This can be related to slight changes of the lattice structure. In case of a dendritic domain the chains are more tilted, the deviation from hexagonal symmetry is more pronounced, and hence the lattice anisotropy is larger. This can be understood also in view of recent simulations considering diffusion-l…

inorganic chemicalsMacromolecular SubstancesSurface PropertiesHigh Energy Physics::LatticeBiophysicsBiophysical PhenomenaDomain formationMonolayerpolycyclic compoundsheterocyclic compoundsMolecular BiologyPhospholipidsPhysics::Atmospheric and Oceanic PhysicsSurface diffusionMolecular StructureChemistryorganic chemicalsHigh Energy Physics::PhenomenologyWaterStereoisomerismCell BiologyCrystallographyMicroscopy FluorescenceDomain (ring theory)health occupationsChirality (chemistry)OilsMolecular Membrane Biology
researchProduct

Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications

2018

Antiphospholipid syndrome (APS) is an acquired autoimmune disease characterized by thromboembolic events, pregnancy morbidity, and the presence of antiphospholipid (aPL) antibodies. There is sound evidence that aPL act as pathogenic autoantibodies being responsible for vascular clots and miscarriages. However, the exact mechanisms involved in the clinical manifestations of the syndrome are still a matter of investigation. In particular, while vascular thrombosis is apparently not associated with inflammation, the pathogenesis of miscarriages can be explained only in part by the aPL-mediated hypercoagulable state and additional non-thrombotic effects, including placental inflammation, have b…

lcsh:Immunologic diseases. Allergy0301 basic medicineImmunologyComplementMiscarriagesAnti-beta2 glycoprotein I antibodieInflammationMiscarriagePathogenesis03 medical and health sciences0302 clinical medicineImmune systemAntiphospholipid syndromeimmune system diseasesAntiphospholipid syndromeMedicineImmunology and AllergyAnimal model030203 arthritis & rheumatologyAutoimmune diseaseInflammationbusiness.industryAutoantibodyThrombosismedicine.diseaseComplement (complexity)Complement systemAnimal models030104 developmental biologyAnti-beta2 glycoprotein I antibodiesPerspectiveThrombosiImmunologyAnimal models; Anti-beta2 glycoprotein I antibodies; Antiphospholipid syndrome; Complement; Inflammation; Miscarriages; Therapy; Thrombosis; Immunology and Allergy; ImmunologyTherapymedicine.symptomlcsh:RC581-607businessFrontiers in Immunology
researchProduct

Glycerosomes:investigation of role of 1,2-dimyristoyl-sn-glycero-3-phosphatidycholine (DMPC) on the assembling and skin delivery performances

2017

Glycerosomes were formulated using 1,2-dimyristoyl-sn-glycero-3-phosphatidycholine (DMPC), diclofenac sodium salt and 10, 20 or 30% glycerol in the water phase, while corresponding liposomes were prepared with the same amount of DMPC and diclofenac, without glycerol. The aim of the present work was to evaluate the effect of the used phospholipid on vesicle features and ability to favour diclofenac skin deposition by comparing these results with those found in previous works performed using hydrogenated soy phosphatidylcholine (P90H) and dipalmitoylphosphatidylcholine (DPPC). Liposomes and glycerosomes were multilamellar, liposomes being smaller (72±6nm). Interactions among glycerol, phospho…

liposomes3003skindimyristoylphosphatidylcholinePhospholipidPharmaceutical Science02 engineering and technologyrehological studies010402 general chemistry01 natural sciencesDSCchemistry.chemical_compoundglycerosomesdrug delivery systemsPhosphatidylcholineGlycerolskin deliveryDSC; glycerosomes; rehological studies; SAXS; skin delivery; animals; diclofenac; dimyristoylphosphatidylcholine; liposomes; skin; swine; drug delivery systems; skin absorption; 3003LiposomeChromatographyBilayerVesicletechnology industry and agricultureswineDiclofenac SodiumSAXS021001 nanoscience & nanotechnologyskin absorption0104 chemical sciencesanimalsdiclofenacchemistryDipalmitoylphosphatidylcholinelipids (amino acids peptides and proteins)0210 nano-technology
researchProduct

Composition influence on pulmonary delivery of rifampicin liposomes.

2012

The effects of lipid concentration and composition on the physicochemical properties, aerosol performance and in vitro toxicity activity of several rifampicin-loaded liposomes were investigated. To this purpose, six liposome formulations containing different amounts of soy phosphatidylcholine and hydrogenated soy phosphatidylcholine, with and without cholesterol and oleic acid, were prepared and fully characterized. Uni- or oligo-lamellar, small (~100 nm), negatively charged (~60 mV) vesicles were obtained. Lipid composition affected aerosol delivery features of liposomal rifampicin; in particular, the highest phospholipid concentration led to a better packing of the vesic…

liposomesaerosolPhospholipidpulmonary deliveryPharmaceutical Sciencelcsh:RS1-441liposomes; rifampicin; cholesterol; oleic acid; rheology; pulmonary delivery; aerosol; cell viability; cellular uptakerifampicinArticlelcsh:Pharmacy and materia medicachemistry.chemical_compoundPhosphatidylcholineMedicinecell viabilityLiposomeChromatographyCholesterolbusiness.industryVesiclecholesterolcellular uptakeIn vitroOleic acidchemistryBiochemistryoleic acidToxicitylipids (amino acids peptides and proteins)rheologybusinessPharmaceutics
researchProduct

Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition.

2021

Abstract Direct oral anti–activated factor X and antithrombin agents have largely replaced vitamin K antagonists as the standard of care in treatment of venous thromboembolism. However, gaps in efficacy and safety persist, notably in end‐stage renal disease, implantable heart valves or assist devices, extracorporeal support of the circulation, and antiphospholipid syndrome. Inhibition of coagulation factor XI (FXI) emerges as a promising new therapeutic target. Antisense oligonucleotides offer potential advantages as a prophylactic or therapeutic modality, with one dose‐finding trial in orthopedic surgery already published. In addition, monoclonal antibodies blocking activation and/or activ…

medicine.drug_class2720 Hematologyvenous thromboembolism610 Medicine & healthBioinformaticslaw.inventionchemistry.chemical_compoundRandomized controlled trialAntiphospholipid syndromelawAntithromboticMedicineDiseases of the blood and blood-forming organsFactor XIIbusiness.industrycatheter(s)Factor X10031 Clinic for AngiologyAntithrombinAnticoagulantanticoagulantHematologycontact systemmedicine.diseasefactor XIPulmonary embolismchemistryRC633-647.5businessState of the Art Isth 2020medicine.drugResearch and practice in thrombosis and haemostasis
researchProduct

IVIG in APS pregnancy

2004

For more than two decades, the intravenous administration of high doses of IgG pooled from the plasma of healthy donors (immune globulin therapy, also known as ‘IVIG’) has benefited patients with a variety of autoimmune disorders. A potential therapeutic role of IVIG in the prevention of thrombosis and of miscarriages in antiphospholipid syndrome (APS) has been postulated. Multicenter randomized controlled trials attempted to define the role of IVIG in preventing pregnancy complications in APS indicate that simple anticoagulation could not be completely satisfactory, and certain patient subgroups might take advantage of IVIG therapy alone or in combination with heparin.

medicine.medical_specialtyAbortion Habitual030204 cardiovascular system & hematologyrecurrent fetal losslaw.invention03 medical and health sciences0302 clinical medicineRheumatologyRandomized controlled trialAntiphospholipid syndromelawPregnancyhemic and lymphatic diseasesInternal medicinemedicineHigh dosesHumans030203 arthritis & rheumatologyIVIGPregnancybiologybusiness.industryPregnancy Complications HematologicImmunoglobulins IntravenousThrombosisHeparinmedicine.diseaseAntiphospholipid SyndromeThrombosisPregnancy ComplicationsImmune Globulin TherapyImmunologybiology.proteinFemaleAntibodybusinessmedicine.drugAPS
researchProduct

Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review.

2018

Direct oral anticoagulants (DOACs) are indicated in the treatment and prevention of venous thromboembolism (VTE). However, the use of DOACs in unusual VTE, including cerebral venous thrombosis (CVT) and splanchnic venous thrombosis (SVT), and in patients with biological thrombophilia including minor thrombophilia (Factor V Leiden and prothrombin G20210A), major innate thrombophilia (protein C and S deficiency, and antithrombin) and major acquired thrombophilia (antiphospholipid syndrome [APS]), remains controversial due to the paucity of available data. There are some reports of DOACs use in the initial treatment or long-term maintenance of patients with either CVT or SVT, but their efficac…

medicine.medical_specialtyAdministration Oral030204 cardiovascular system & hematologyThrombophilialaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialAntiphospholipid syndromelawInternal medicinemedicineFactor V LeidenHumansThrombophilia030212 general & internal medicineVenous ThrombosisClinical Trials as Topicbusiness.industryAntithrombinAnticoagulantsHematologymedicine.diseaseAntiphospholipid Syndrome3. Good healthVenous thrombosisTreatment OutcomeOncologyProthrombin G20210AbusinessProtein Cmedicine.drugBlood reviews
researchProduct

Altered receptor binding densities in experimental antiphospholipid syndrome despite only moderately enhanced autoantibody levels and absence of beha…

2013

Abstract Experimental antiphospholipid syndrome (eAPS) in Balb/c mice causes neuropsychiatric abnormalities including hyperactivity, increased explorative behavior and cognitive deficits. Recently, we have demonstrated that these behavioral changes were linked to an upregulation of serotonergic 5-HT1A receptor binding densities in cortical and hippocampal regions while excitatory and inhibitory neurotransmitter receptors remain largely unchanged. To examine whether the observed behavioral features depend on a critical antibody concentration, mice with only moderately enhanced antiphospholipid antibodies (aPL), about 50–80% of high levels, were analyzed and compared to controls. The staircas…

medicine.medical_specialtyBehavior AnimalChemistryGABAA receptorImmunologyHematologyAMPA receptorNeuropsychological TestsAntiphospholipid SyndromeSerotonergicReceptors NeurotransmitterDisease Models AnimalMiceEndocrinologyNeurotransmitter receptorInternal medicineMuscarinic acetylcholine receptormedicineAnimalsImmunology and AllergyNMDA receptorFemaleReceptor5-HT receptorAutoantibodiesImmunobiology
researchProduct

The release of choline from phospholipids mediated by beta-adrenoceptor activation in isolated hearts.

1986

The resting efflux of choline into the perfusate (Tyrode's solution) of isolated hearts was equal to the rate, at which choline was liberated from phospholipid degradation (Lindmar et al. 1986). Infusion of isoprenaline (2 X 10(-7) mol/l), forskolin (1-3 X 10(-6) mol/l) or 3-isobutyl-1-methylxanthine (IBMX; 3 X 10(-4) mol/l) for 40 min markedly enhanced the efflux of choline. The increase was linear during the experimental period and, in the case of isoprenaline, was blocked by 3 X 10(-7) mol/l atenolol. In the guinea-pig heart, IBMX at a threshold concentration of 10(-4) mol/l shifted the concentration-response curve for the effect of forskolin on the efflux of choline to the left by one l…

medicine.medical_specialtyCarbacholIBMXGuinea PigsPhospholipidIn Vitro TechniquesCholinechemistry.chemical_compoundInternal medicineIsoprenaline1-Methyl-3-isobutylxanthineReceptors Adrenergic betamedicineCyclic AMPCholineAnimalsPhospholipidsCholinesterasePharmacologyForskolinbiologyMyocardiumColforsinGeneral MedicineMyocardial ContractionReceptors MuscarinicEndocrinologychemistryQuinacrinebiology.proteinCalciumChickensAcetylcholinemedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

THU0582 Prognostic Factors of Macrophage Activation Syndrome in Adults: Analysis of 40 Cases in 2 Tertiary Referral Centers

2016

Background Macrophage activation syndrome (MAS) is a rare, life-threatening disease in which early diagnosis and aggressive therapeutic strategy may improve the outcome [1]. Due to its rarity, epidemiologic data are still lacking. Hyperferritinemia is frequently associated with MAS and might modulate the cytokines storm the latter contributing to the development of multi-organ failure [2]. Objectives In the current study, we aimed to investigate clinical data, treatments, and outcome of adult MAS patients secondary to autoimmune rheumatic disease. Methods We retrospectively investigated clinical data, treatments, and outcome of 40 adult MAS patients secondary to autoimmune rheumatic disease…

medicine.medical_specialtyImmunologyCatastrophic antiphospholipid syndromeGastroenterologyGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundTocilizumabRheumatologyInternal medicinemedicineImmunology and AllergyMacrophage activation syndrome adult onset Still‟s disease hyperferritinemic syndromebusiness.industrySeptic shockProportional hazards modelMortality ratehyperferritinemic syndromeadult onset Still‟s diseasemedicine.diseaseComorbiditySurgeryMethylprednisolonechemistryMacrophage activation syndromeMacrophage activation syndromebusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct